Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal propranolol for persistent clinically significant diabetic macular edema
IRCT20231027059872N1Phase 2Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of propranolol in diabetic macular edema (DME), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Improvement of macular edema in diabetic patients resistant to Avastin, Improvement of edema in treatment-resistant macular edema and 3 more. Started Nov 2023; status: completed.
02
Drugs
propranolol
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on IRCT20231027059872N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231027059872N1.